Abstract
Purpose
To investigate the effect of botulinum neurotoxin-A (BTX-A) treatment on dry eye symptoms, tear meniscus, corneal topography and corneal aberrometry in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS).
Materials and methods
This prospective study comprised of 6 patients with BEB and 20 patients with HFS. Tear meniscus height (TMH) and depth (TMD), tear break-up time (TBUT), corneal fluorescein staining score (CFSS), Schirmer I test, ocular surface disease index (OSDI) score, corneal topography [corneal power of flat axis (K1), corneal power of steep axis (K2), mean corneal power (Km), astigmatism and thinnest pachymetry] and anterior corneal aberrometry [spherical aberration (SA), vertical coma (vcoma), horizontal coma (hcoma), higher order root mean square (hRMS) and total RMS] were evaluated before BTX-A treatment, 3 weeks after BTX-A treatment and 2 months after BTX-A treatment.
Results
Six patients with BEB and 20 patients with HFS treated with BTX-A were evaluated in this study. Twenty contralateral spasm free eyes of 20 HFS patients were taken as control group. TMH and TMD were found to be significantly higher in eyes with spasm at both 3 weeks and 2 months after injection (TMH: 279.0 ± 123.2 at pretreatment, 380.5 ± 174.7 at third week and 317.0 ± 125.5 at second month p < 0.001 and p = 0.02, respectively), (TMD: 183.7 ± 59.7 at pretreatment, 235.7 ± 91.1 at third week and 209.8 ± 77.1 at second month p < 0.01 and p = 0.015, respectively). TBUT, CFSS, Schirmer I test values were similar (p > 0.05). OSDI scores decreased significantly from 29.6 ± 25.3 to 19.8 ± 20. p = 0.03 at third week and increased again by second month. K2 (43.9 ± 1.7 vs. 43.7 ± 1.6, p = 0.03) and astigmatism (0.8 ± 0.5 vs. 0.6 ± 0.4, p = 0.04) values were significantly lower at third week and increased again by second month. Pachymetry and aberrometric values did not change significantly. In the control group only Schirmer I test value decreased significantly at second month (10.5 ± 6.5 vs. 7.2 ± 5.6, p = 0.008), other parameters did not change.
Conclusion
BTX-A injection increases tear meniscus and decrease symptoms related to dry eye disease in BEB and HFS patients. It decrease astigmatism and keratometry values, it does not cause a significant change in corneal aberrations. However the positive effects of BTX-A injection on ocular surface is temporary.
Similar content being viewed by others
Data availability
The manuscript has no associated data in a data repository.
References
Anderson RL, Patel B, Holds JB, Jordan DR (1998) Blepharospasm: past, present, and future. Ophthalm Plast Reconstr Surg 14(5):305–317
Chaudhry N, Srivastava A, Joshi L (2015) Hemifacial spasm: the past, present and future. J Neurol Sci 356(1–2):27–31
Osako M, Keltner JL (1991) Botulinum A toxin (Oculinum®) in ophthalmology. Surv Ophthalmol 36(1):28–46
Park DI, Shin HM, Lee SY, Lew H (2013) Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm. Acta Ophthalmol 91(2):e108–e112
Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q (2014) The influence of benign essential blepharospasm on dry eye disease and ocular inflammation. Am J Ophthalmol 157(3):591–597. https://doi.org/10.1016/j.ajo.2013.11.014
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, Liu Z, Nelson JD, Nichols JJ, Tsubota K (2017) TFOS DEWS II definition and classification report. Ocul Surf 15(3):276–283
Ho MC, Hsu WC, Hsieh YT (2014) Botulinum toxin type a injection for lateral canthal rhytids: effect on tear film stability and tear production. JAMA Ophthalmol 132(3):332–337. https://doi.org/10.1001/jamaophthalmol.2013.6243
Bilyk JR, Yen MT, Bradley EA, Wladis EJ, Mawn LA (2018) Chemodenervation for the treatment of facial dystonia: a report by the American academy of ophthalmology. Ophthalmology 125(9):1459–1467
Gunes A, Demirci S, Koyuncuoglu HR, Tok L, Tok O (2015) Corneal and tear film changes after botulinum toxin-A in blepharospasm or hemifacial spasm. Cornea 34(8):906–910. https://doi.org/10.1097/ICO.0000000000000482
Palakuru JR, Wang J, Aquavella JV (2007) Effect of blinking on tear dynamics. Invest Ophthalmol Vis Sci 48(7):3032–3037
Ang M, Baskaran M, Werkmeister RM, Chua J, Schmidl D, dos Santos VA, Garhoefer G, Mehta JS, Schmetterer L (2018) Anterior segment optical coherence tomography. Prog Retin Eye Res 66:132–156
Shen M, Li J, Wang J, Ma H, Cai C, Tao A, Yuan Y, Lu F (2009) Upper and lower tear menisci in the diagnosis of dry eye. Invest Ophthalmol Vis Sci 50(6):2722–2726
Nguyen P, Huang D, Li Y, Sadda SR, Ramos S, Pappuru RR, Yiu SC (2012) Correlation between optical coherence tomography-derived assessments of lower tear meniscus parameters and clinical features of dry eye disease. Cornea 31(6):680
Choi EW, Yeom DJ, Jang SY (2021) Botulinum toxin a injection for the treatment of intractable dry eye disease. Medicina 57(3):247
Moon NJ, Lee HI, Kim JC (2006) The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm. J Korean Med Sci 21(1):131–135
Koh S (2018) Irregular astigmatism and higher-order aberrations in eyes with dry eye disease. Investig Ophthalmol Vis Sci 59(14):DES36–DES40
Isshiki Y, Ishikawa H, Mimura O (2016) Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm. Jpn J Ophthalmol 60(6):486–491
Yabiku MM, Sartori FJ, Sarraff EP, Osaki TH, Hossaka SK, Pereira CI, Freitas W, Osaki MH, Cariello AJ (2011) Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin. Arq Bras Oftalmol 74(6):414–416
Denoyer A, Rabut G, Baudouin C (2012) Tear film aberration dynamics and vision-related quality of life in patients with dry eye disease. Ophthalmology 119(9):1811–1818
Lemp A (1995) Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. Eye Contact Lens 21(4):221–232
Mauriello JA Jr, Coniaris H, Haupt EJ (1987) Use of botuiinum toxin in the treatment of one hundred patients with facial dyskinesias. Ophthalmology 94(8):976–979
Jost WH, Kohl A (2001) Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 248(1):I21–I24
Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, Marchese R, Raineri R, Roselli F, Livrea P (2002) Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 59(3):418–420
Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS (2014) Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection. Eur J Ophthalmol 24(6):830–834
Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober E, Schmut O (2003) Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye. Br J Ophthalmol 87(1):54–56
Ziahosseini K, Al-Abbadi Z, Malhotra R (2015) Botulinum toxin injection for the treatment of epiphora in lacrimal outflow obstruction. Eye 29(5):656
Sahlin S, Linderoth R (2008) Eyelid botulinum toxin injections for the dry eye. In: Surgery for the dry eye, vol 41. Karger Publishers, pp 187–192
Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT (2018) Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm. Sci Rep 8(1):8367. https://doi.org/10.1038/s41598-018-26750-5
Willcox MD, Argüeso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, Papas EB, Rolland JP, Schmidt TA, Stahl U (2017) TFOS DEWS II tear film report. Ocul Surf 15(3):366–403
Wang J, Aquavella J, Palakuru J, Chung S, Feng C (2006) Relationships between central tear film thickness and tear menisci of the upper and lower eyelids. Invest Ophthalmol Vis Sci 47(10):4349–4355
Savini G, Barboni P, Zanini M (2006) Tear meniscus evaluation by optical coherence tomography. Ophthalm Surg Lasers Imaging Retina 37(2):112–118
Demirok GS, Gurdal C, Sarac O, Ceran BB, Can I (2013) Evaluating of tear meniscus parameters with optical coherent tomography in dry-eye patients/Kuru Goz Hastalarinda Optik Koherans Tomografi ile Gozyasi Meniskus Parametrelerinin Degerlendirilmesi. Turkish J Ophthalmol 43(4):258–263
Schein OD, Tielsch JM, Muñoz B, Bandeen-Roche K, West S (1997) Relation between signs and symptoms of dry eye in the elderly: a population-based perspective. Ophthalmology 104(9):1395–1401
Kim YK, In JH, Jang SY (2016) Changes in corneal curvature after upper eyelid surgery measured by corneal topography. J Craniofac Surg 27(3):e235–e238
Mavrikakis I, Beckingsale P, Lee E, Riaz Y, Brittain P (2006) Changes in corneal topography with upper eyelid gold weight implants. Ophthalm Plast Reconstr Surg 22(5):331–334
Osaki T, Osaki MH, Osaki TH, Hirai FE, Campos M (2016) Differences in corneal parameters between affected and normal contralateral eyes in patients with hemifacial spasm treated with botulinum toxin-A: outcomes during one complete treatment cycle. Cornea 35(2):220–225
McAlinden C, Khadka J, Pesudovs K (2011) A comprehensive evaluation of the precision (repeatability and reproducibility) of the Oculus Pentacam HR. Invest Ophthalmol Vis Sci 52(10):7731–7737. https://doi.org/10.1167/iovs.10-7093
Rieger G (1992) The importance of the precorneal tear film for the quality of optical imaging. Br J Ophthalmol 76(3):157–158
Koh S, Maeda N, Kuroda T, Hori Y, Watanabe H, Fujikado T, Tano Y, Hirohara Y, Mihashi T (2002) Effect of tear film break-up on higher-order aberrations measured with wavefront sensor. Am J Ophthalmol 134(1):115–117
Montés-Micó R, Alió JL, Munoz G, Charman WN (2004) Temporal changes in optical quality of air–tear film interface at anterior cornea after blink. Invest Ophthalmol Vis Sci 45(6):1752–1757
Montés-Micó R, Alió JL, Muñoz G, Pérez-Santonja JJ, Charman WN (2004) Postblink changes in total and corneal ocular aberrations. Ophthalmology 111(4):758–767
Montés-Micó R, Cáliz A, Alió JL (2004) Wavefront analysis of higher order aberrations in dry eye patients. J Refract Surg 20(3):243–247
Jariyakosol S, Uthaithammarat L, Chatwichaikul N, Kasetsuwan N, Chongpison Y (2021) Dry eye disease in hemifacial spasm patients treated with botulinum toxin type A. Clinical Ophthalmology (Auckland, NZ) 15:1775
Ababneh OH, Cetinkaya A, Kulwin DR (2014) Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 42(3):254–261
Pellegrini M, Schiavi C, Taroni L, Sebastiani S, Bernabei F, Roda M, Moscardelli F, Giannaccare G (2019) Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study. Indian J Ophthalmol 67(9):1405
Funding
None.
Author information
Authors and Affiliations
Contributions
Dr. Bayraktar Bilen—Data collection, manuscript submission and coordination, statistical analysis; Dr. Bilen—Coordination and data collection; Dr. Topçu Yılmaz—Data and Manuscript Editing; and Evren Kemer—Consultants to the procedure.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ankara Numune Education and Research Hospital E-19-2606) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Animal research
This article does not contain any studies with animals performed by any of the authors.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent to publish
Informed consent for potential research publication was obtained from all individual participants included in the study at the time of their treatments performed.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bayraktar Bilen, N., Bilen, Ş., Topçu Yılmaz, P. et al. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm. Int Ophthalmol 42, 2625–2632 (2022). https://doi.org/10.1007/s10792-022-02253-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-022-02253-1